Answers are grounded in this paper and cite their sources.
Targeting neutrophils has emerged as a promising therapeutic strategy for various inflammatory diseases. In this study, we investigate a highly specific monoclonal antibody that targets human CXCR2, which is a major chemokine receptor on neutrophils. This antibody functions as an inverse agonist, binds tightly to CXCR2 in a mutually exclusive manner versus its cognate ligands, such as interleukin-8, and completely blocks CXCR2- β -arrestin signaling and subsequent neutrophil functions. Treatment with the antibody appears to result in an overall reversal of IL-8 induced gene expressions in primary human neutrophils. We conducted in vivo studies using four mouse models of inflammation. In all four, the antibody demonstrates remarkable efficacy in controlling dysregulated neutrophil activation in peripheral circulation and inflammatory tissues. In addition, administration of the antibody not only ameliorates the symptoms of neutrophilia, but also mitigates tissue damage in cases of acute lung inflammation and delayed-type-hypersensitivity reactions. Moreover, treatment with the antibody before the initiation or at the peak of inflammation consistently yields beneficial results.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: